SCHEMBL160095

SCHEMBL160095

CCCCNC(=O)c1cncc([O])n1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
HTT P42858 3/20 0.46
TSHR P16473 2/20 0.46
NAAA Q02083 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
HIF1A Q16665 1/20 0.42
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
DRD2 P14416 1/20 0.40
DRD3 P35462 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164739 0.90 KDM4E (0.47) KDM4ESMN1; SMN2RAB9ANPC1LMNA
SCHEMBL166011 0.83 CNR1 (0.47) KDM4ESMN1; SMN2
SCHEMBL163201 0.76 RAB9A (0.44) KDM4EHTTSMN1; SMN2RAB9ANPC1
SCHEMBL6359528 0.76 KDM4E (0.88) KDM4ESMN1; SMN2RAB9ANPC1LMNA
SCHEMBL164543 0.74 CNR1 (0.42) KDM4ETSHRRAB9ANPC1LMNA
SCHEMBL18157897 0.73 LMNA (0.68) KDM4EHTTTSHRNAAASMN1; SMN2
SCHEMBL10245956 0.73 SMN1; SMN2 (0.49) KDM4EHTTTSHRNAAASMN1; SMN2
SCHEMBL7109274 0.72 CNR1 (0.50) KDM4EHTTRAB9ANPC1LMNA
SCHEMBL9755022 0.72 KDM4E (0.97) KDM4ENAAASMN1; SMN2RAB9ANPC1
SCHEMBL160350 0.72 HTT (0.46) KDM4EHTTTSHRNAAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 KDM4E 2214/4885HTT 72/4885TSHR 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.